-+ 0.00%
-+ 0.00%
-+ 0.00%

Shanghai Henlius Wins Australian Approval for Phase 1 Trial of HLX109

PUBT·11/04/2026 08:34:14
Shanghai Henlius Wins Australian Approval for Phase 1 Trial of HLX109
  • Shanghai Henlius Biotech received clearance to begin a Phase 1 trial of HLX109 for generalized pustular psoriasis in Australia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261104-12399090), on November 04, 2026, and is solely responsible for the information contained therein.